USPTO Examiner VIGIL TORIANA NICHOLE - Art Unit 1612

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18684596NOVEL COMPOUND AND USE OF SAID COMPOUNDFebruary 2024February 2026Allow2400NoNo
18260112HAIR CONDITIONER FORMULATIONJune 2023March 2026Allow3210NoNo
18200812METHODS OF OTOPROTECTION AGAINST PLATINUM-BASED ANTINEOPLASTIC AGENTSMay 2023February 2026Allow3320NoNo
18199903COMBINED PHARMACEUTICAL FORMULATION COMPRISING GEMCITABINE-CONTAINING LIPOSOME COMPOSITION AND IMMUNE CHECKPOINT INHIBITORMay 2023November 2025Abandon3010NoNo
18025444HERBICIDAL COMBINATIONS COMPRISING DIFLUFENICAN AND MESOTRIONEMarch 2023January 2026Allow3411NoNo
18161356STABLE MICRONUTRIENT COMPLEX FOR USE IN AGRICULTURAL APPLICATIONSJanuary 2023March 2026Allow3720NoNo
18101055TREATING MICROVASCULAR DYSFUNCTIONJanuary 2023August 2025Allow3120NoNo
18006617VISCOUS AQUEOUS COMPOSITION AND SKIN EXTERNAL PREPARATIONJanuary 2023October 2025Allow3320NoNo
18016672SOL-GEL CONVERSION OVER TIME OF 6-ARM PEG HYDROGELJanuary 2023February 2026Abandon3710NoNo
18153467COMPOSITION FOR SUPPRESSING SKIN IRRITATION OR INHIBITING SEBUM SECRETIONJanuary 2023November 2025Allow3420YesNo
18096227METHOD AND PHARMACEUTICAL COMPOSITION FOR RESCUING RETINAL DEGENERATIONJanuary 2023April 2025Allow2710NoNo
18153514TOPICAL COMPOSITIONS FOR TREATING OR PREVENTING SCARS AND METHODS FOR THEIR USEJanuary 2023March 2026Abandon3811NoNo
18094156Composition and Method for Preventing or Treating Opioid Withdrawal SymptomsJanuary 2023November 2025Allow3421YesNo
18093714HAIR COMPOSITE FOR HAIR THICKENING AND HAIR GROWTHJanuary 2023June 2025Abandon3010NoNo
18069304Production of Silicate Solutions and their UsesDecember 2022January 2026Allow3721NoNo
18010752ACTIVE COMPOUND COMBINATIONSDecember 2022February 2026Allow3811NoNo
18009603NOVEL USEDecember 2022September 2025Abandon3310NoNo
17922259COSMETIC COMPOSITION IN AEROSOL FORM, METHOD FOR PRODUCTION AND USEOctober 2022July 2025Abandon3310NoNo
17997202USE OF POLYETHERS AS CARRIER FOR ACTIVE INGREDIENTSOctober 2022November 2025Allow3621YesNo
17918967STICK-TYPE OIL-DISPERSION COSMETIC COMPOSITION COMPRISING POWDEROctober 2022November 2025Abandon3720NoNo
17996150TERPENE-CONTAINING COMPOSITION AND ITS COSMETIC USEOctober 2022August 2025Allow3411NoNo
17918361PERSONAL CARE COMPOSITION WITH VISUALLY DISTINCT AQUEOUS AND OIL PHASEOctober 2022February 2026Abandon4021NoNo
18045818ENVIRONMENTALLY FRIENDLY LIQUID AND USES THEREOFOctober 2022June 2025Abandon3210NoNo
17957402TAILORED LIPOSOMES FOR THE TREATMENT OF BACTERIAL INFECTIONSSeptember 2022December 2025Allow3830YesNo
17954214COMPOSITIONS AND METHODS RELATING TO PIGMENTATIONSeptember 2022October 2025Allow3720YesNo
17755183BIODEGRADABLE STRETCH FILMSeptember 2022December 2025Abandon4411NoNo
17906326METHOD FOR PRODUCING PARTICLESSeptember 2022August 2025Allow3520YesNo
17910244A PERSONAL CARE COMPOSITIONSeptember 2022December 2025Allow3911NoNo
17904664SELF-EMULSIFYING COMPOSITION, INTENDED FOR ADMINISTRATION ONTO THE SKIN, CONTAINING BIOSURFACTANT, COSURFACTANT AND OIL PHASEAugust 2022March 2025Allow3110NoNo
17882144LIPOSOME COMPOSITION AND PHARMACEUTICAL COMPOSITIONAugust 2022September 2025Abandon3710NoNo
17798064COMPOSITIONS OF ALUM NANOPARTICLES FOR IMMUNOMODULATION AND METHODS FOR PRODUCING THE SAMEAugust 2022September 2025Abandon3701NoNo
17831071Method for Preparing Transmembrane pH-Gradient VesiclesJune 2022June 2025Allow3720NoNo
17824901DEVICES AND METHODS FOR THE TRANSDERMAL DELIVERY OF PSILOCYBINMay 2022June 2025Abandon3610YesNo
17753847WATER-IN-OIL EMULSIFIABLE FORMULATION CONTAINING A SULFOPOLYMERMarch 2022October 2025Abandon4310NoNo
17680152On Demand Drug Release SystemFebruary 2022October 2025Abandon4301NoNo
17360927ZINC MELOXICAM COMPLEX MICROPARTICLES AND ANESTHETIC FORMULATIONS AND PROCESSES FOR MAKING THE SAMEJune 2021August 2025Abandon5010NoNo
17344039ZINC MELOXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND PROCESSES FOR MAKING THE SAMEJune 2021October 2025Allow5230NoNo
17202278ROOT NODULE GROWTH-PROMOTING BACTERIUM MICROBACTERIUM SP. X-18 AND APPLICATION THEREOFMarch 2021October 2025Abandon5510NoNo
17274850SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING OF A SEDATIVE DRUG AND USES THEREOFMarch 2021January 2026Allow5841NoNo
16568801PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF WEAK ACID DRUGS AND USES THEREOFSeptember 2019August 2025Abandon6091YesNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner VIGIL, TORIANA NICHOLE - Prosecution Strategy Guide

Executive Summary

Examiner VIGIL, TORIANA NICHOLE works in Art Unit 1612 and has examined 5 patent applications in our dataset. With an allowance rate of 40.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 55 months.

Allowance Patterns

Examiner VIGIL, TORIANA NICHOLE's allowance rate of 40.0% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by VIGIL, TORIANA NICHOLE receive 3.60 office actions before reaching final disposition. This places the examiner in the 95% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by VIGIL, TORIANA NICHOLE is 55 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a -50.0% benefit to allowance rate for applications examined by VIGIL, TORIANA NICHOLE. This interview benefit is in the 0% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 16.7% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 0% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Petition Practice

When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.